© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Gadotic acid came onto the scene as a response to the growing medical need for safer, more precise imaging techniques. In the race to improve MRI diagnostics, research teams tried a range of compounds before zeroing in on gadolinium as a promising core. Early experiments in the late twentieth century struggled with toxicity and instability until the concept of chelation caught hold. Scientists realized that by locking gadolinium ions inside sturdy organic cages, they could harness the element’s magnetic power without letting its toxic nature spill over to patients. Approved gadolinium-based agents such as gadoteric acid (often called Dotarem) gained steam in the clinic through exhaustive human and animal studies, jumpstarting a new era in radiology. The arrival of these contrast agents allowed doctors to spot lesions, tumors, or vascular issues with a confidence that previous tools just couldn’t support. Commercialization followed institutional and regulatory buy-in, and by the early 2000s, the product saw global use, riding the momentum of rising MRI adoption.
Gadotic acid typically appears in pharmaceutical-grade vials or pre-filled syringes intended for intravenous delivery. The solution is clear, colorless, and engineered to avoid precipitation during storage. Each batch undergoes rigorous sterility and trace contamination checks. Packaging specifies the precise gadolinium ion content, making dosing predictable for busy hospital wards and clinics. What sets this product apart from older agents is its high thermodynamic stability. As a chelate, each molecule tightly binds gadolinium within a macrocyclic scaffold, reducing the risk of free gadolinium ions entering tissues. It carries names like Gadoterate meglumine when paired with the meglumine salt, but clinicians and technicians often know it more simply by trade labels such as Dotarem.
Gadotic acid presents as a white to off-white crystalline powder in its pure form, highly soluble in water, and with a molecular weight around 558 g/mol. Its solubility plays a key role in medical use, as it allows for easy injection and rapid dispersal in the bloodstream. The molecule features a strong macrocyclic structure, forming a kinetically inert complex with the gadolinium ion. It shows robust resistance to dissociation under physiological pH, temperature, and pressure. As a chelating agent derived from DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), its chemical backbone supports both hydrophilicity and minimal protein binding. High thermal stability and low osmolality provide further assurances for clinical safety. Lab samples reveal a melting point above 300°C, with no notable decomposition issues during standard handling or imaging procedures.
Each vial or ampoule of gadotic acid-based contrast agent comes with a tightly regimented content statement, highlighting total gadolinium concentration, the strength per mL, and pH range (usually 6.5–8). Pharmaceutical sheets specify excipients like water for injection and potential stabilizers. Lot numbers, manufacturing dates, and expiration dates must be present, meeting health authority standards around traceability. Instructions caution against mixing with other drugs unless confirmed compatible through testing. Labels deliver clear warnings on contraindications, allergies, dosage, and detailed instructions for use alongside MRI. Safety documentation ensures easy access to information on storage and reconstitution, reinforcing responsible use and minimal risk in the clinic.
Synthesis of gadotic acid starts from DOTA, crafted via cyclen chemistry and carboxyl functionalization. After purifying the DOTA ligand, chemists introduce gadolinium nitrate or chloride under controlled pH and temperature, allowing the ring structure to wrap tightly around the metal ion. The reaction demands patience, cleanroom environments, and precise time and mixing checks to avoid unwanted contaminants or side products. The resulting solution undergoes repeated purification, often via ultrafiltration, to achieve the desired pharmaceutical-grade purity. Solid forms can be lyophilized for storage and later dissolved as needed. Meglumine may be added for improved solubility or better patient tolerability. Once complete, rigorous testing for heavy metals, free gadolinium, and bioburden ensures each batch meets regulatory standards. Manufacturing runs stick to cGMP principles, given the critical impact of even tiny impurities on patient safety.
Gadotic acid boasts chemical resilience thanks to its macrocyclic backbone, but it is not immune to all reactions. Under extreme acidic or basic conditions, the chelate can hydrolyze, releasing gadolinium ions and potentially rebuilding the free DOTA scaffold. Researchers have explored modifications to the DOTA ring, aiming to accelerate clearance or optimize relaxivity. Swapping side chains or using alternative carboxylic acids can tweak hydrophilicity or binding kinetics. In analytical labs, dissociation is sometimes forced under controlled settings to quantify free gadolinium through spectrometric techniques. Emerging efforts in nanomedicine focus on conjugating gadotic acid to peptides, antibodies, or nanoparticles, aiming to target tumors or inflammation more directly. These changes hold promise but also raise concerns about altered pharmacodynamics and possible tissue retention.
Gadotic acid operates under several formal and informal names, shaped by local regulatory conventions and market strategies. Its IUPAC name is a mouthful, often shortened in research as Gd-DOTA. Common dictionaries list synonyms such as gadoterate, gadolinium-DOTA, and hexadentate gadolinium complex. In practice, clinicians know the compound by major trade names like Dotarem in Europe and other equivalents in global markets. Pharmacy shelves and hospital records log batch information under these names to avoid confusion during procurement and patient care. Researchers tend to refer to either the acid form or its meglumine salt, depending on the preparation method, but structurally the core remains the same: a macrocyclic cage trussed tightly around a Gd3+ ion.
Clinical safety dominated early trials, and it still forms the backbone of gadotic acid’s reputation. Macrocyclic chelators stand out by holding onto gadolinium far more tightly than older linear types, reducing risks linked to nephrogenic systemic fibrosis, especially in vulnerable patients with kidney problems. Hospitals maintain strict protocols: allergy screening, real-time patient monitoring, and full documentation for every injection. During MRI work, only trained staff can administer the dose, with resuscitation equipment ready in case of rare severe reactions. Waste handling includes clear guidelines for disposal, as gadolinium, even chelated, should not enter waste streams uncontrolled. Regulatory bodies from the EMA to the FDA inspect manufacturing plants frequently, enforcing trace element monitoring and recall procedures. Staff education keeps pace with updated recommendations, as studies on subtle tissue retention continue to shape usage recommendations.
The clinical utility of gadotic acid centers on high-resolution MRI scans, particularly for neurological, vascular, and oncological imaging. Radiologists rely on it to reveal abnormal tissue where blood-brain barrier breakdown, angiogenesis, or high perfusion mark pathology. Patients undergoing scans for brain tumors, multiple sclerosis, or stroke benefit from the contrast, as it sharply defines active lesions or differentiates scar tissue from tumor recurrence. Pediatric neuroradiology often favors macrocyclic agents like gadotic acid for their minimal renal liability. Beyond neurology, the agent finds work in cardiac imaging, musculoskeletal assessments, and chronic inflammatory disease tracking. Research teams continue to explore its ability to illuminate subtle changes in tissue microstructure. Personalized medicine approaches see its use expand further, especially as imaging techniques demand both safety and sharper resolution.
Innovation marches forward, with teams exploring both new chelation strategies and better targeting. Work on conjugating gadotic acid to tumor-seeking molecules or nanoparticles looks to move MRI beyond “static” scans into the world of molecular imaging. Engineers seek to tune relaxivity, magnetic properties, or kinetic profiles through creative ligand modifications. With concerns about cumulative gadolinium exposure in repeat patients, researchers aim for agents with even faster clearance or those that break down beyond the body, slashing long-term risks. High-throughput screening and computational modeling now cut guesswork, helping teams predict the best ligand shapes before the first synthesis. Clinical trials examine safety and signal characteristics in healthy volunteers and special populations, balancing imaging needs with long-term risks.
The spotlight often shines on gadolinium’s toxicity, as case reports in the late 2000s drew attention to risks in at-risk populations. Linear agents fell out of favor after links to nephrogenic systemic fibrosis (NSF) in kidney-impaired patients. Macrocyclic agents like gadotic acid earned trust for retaining gadolinium in a closed grip. Toxicology studies scrutinize not only immediate allergic reactions but long-term deposition: traces of gadolinium sometimes show up in brain or bone tissue, sparking debates on downstream risks. So far, population studies and animal models suggest low harm with macrocyclic agents at approved doses, but research keeps running to settle lingering worries. Careful screening, dose limitation, and vigilance for delayed reactions stand as daily practices. Regulatory agencies require continual safety updates, drawing from post-marketing surveillance to refine risk profiles and patient guidance.
Advances in MRI technology and the demand for sharper diagnostics keep fueling research into gadotic acid’s next chapter. Synthetic chemistry stands ready to deliver ligands that bind even tighter or clear even faster. Teams envision “smart” agents, combining gadolinium’s magnetic core with antibodies, peptides, or other markers to home in on not just anatomy but function, metabolism, or even specific cell populations. Artificial intelligence and software-driven imaging will ask more from contrast agents, calling for both stronger and safer products. Concerns around trace tissue retention propel the hunt for biodegradable chelates or entirely new metals. As regulatory and patient safety expectations heighten, transparent reporting and continuous improvement will lead product development. In clinics, the challenge will always be balancing image clarity, patient throughput, and long-term safety—goals tied deeply to the chemistry and stewardship behind gadotic acid.
Gadotic acid turns up most often in radiology, lighting up details that standard scans miss. You see it used mainly as a contrast agent in magnetic resonance imaging (MRI). Doctors count on clear images, especially when hunting for issues in the brain, spine, or joints. I remember my first exposure to a hospital MRI room: patients always a bit anxious, staff reassuring them about a harmless “dye” that helps doctors see inside the body. That dye was often a gadolinium-based agent—gadotic acid being one example.
Without contrast agents like gadotic acid, some tumors, scars, or blood vessel oddities stay hidden. Take brain scans: a tumor hiding in healthy tissue can look nearly invisible. With gadotic acid, it suddenly pops out on the screen, giving doctors a real chance to plan the right treatments. For someone experiencing seizures or headaches, that sharp image can mean an early diagnosis and a better outcome. I’ve seen families go from confusion to relief when radiologists find answers in those sharper images.
Gadotic acid has a solid safety record when doctors use it as directed. Not everyone qualifies, though. People with severe kidney problems face higher risks because their bodies can’t clear gadolinium as quickly. Some rare cases of a condition called nephrogenic systemic fibrosis (NSF) have been linked to these agents in patients with kidney troubles. This does not happen to everyone, and doctors check kidney function before ordering tests using gadotic acid.
The medical community keeps an eye on side effects. Mild headaches, nausea, or a warm feeling can happen. Severe allergic reactions are extremely rare, yet staff train for any emergency. Open conversations between patients and their doctors help spot risks before the scan happens. I’ve watched radiology nurses patiently answer family questions, explaining what could go wrong and why most patients breeze right through without trouble. That kind of honesty helps people feel more comfortable about their care.
Clear imaging does more than diagnose. It helps decide whether a child needs brain surgery, helps an athlete recover from a joint injury, or lets cancer doctors track whether treatment shrinks a tumor. One patient story sticks with me: a young teacher, nervous after some odd vision changes, gets a scan that pinpoints the issue. Early, accurate diagnosis changes her course—a quick surgery, and she gets her normal life back. Gadotic acid does not cure, but without it, the path forward gets cloudy.
Medicine keeps moving forward. Researchers build better, safer contrast agents and find ways to use less of them. Radiology teams use tailored doses instead of a one-size-fits-all approach. Every scan uses the lowest possible amount to get the answers doctors need. Patients with kidney disease often get alternative agents or sometimes no contrast at all, depending on the scan’s urgency. That personal touch makes a real difference.
Healthcare systems also push for better tracking after scans, making sure that anyone who does have a reaction gets fast help. A few countries track the long-term effects of gadolinium exposure, gathering evidence to support safer guidelines everywhere. Real progress takes clear info, honest conversations, and teamwork from everyone involved.
People want to know what’s going into their bodies. Hospitals and imaging centers give out printed materials, talk kids through their first scans, and call families to follow up after appointments. I’ve met patients who feel less afraid once they know why the scan matters and what the risks look like. That trust forms the backbone of good care. Gadotic acid serves as a tool—one that, used with care and respect for the patient, lets modern medicine keep its promises of clarity and accurate answers.
Gadotic acid shows up in MRI clinics, often under the brand name Dotarem. Radiologists use it as a contrast agent to help highlight details in scans that would otherwise blend into the background. This clarity really makes a difference for figuring out what’s happening inside the body, but each dose also means careful consideration for patient safety.
After a scan, most folks walk away with no complaints. Some might notice a metallic taste in their mouth, sometimes while lying inside the scanner. There can also be mild reactions like a headache, a bit of nausea, or warmth at the injection spot. Data collected by the U.S. Food and Drug Administration suggests mild reactions show up in less than 2 percent of patients who receive gadolinium-based agents such as gadotic acid. Usually, these symptoms fade before people even leave the hospital or clinic.
For a small number, issues get more serious. Allergic responses — things like trouble breathing, hives, or drops in blood pressure — send a scan day off the rails quickly. Emergency staff stay close for these situations. Reports in American Journal of Roentgenology found severe reactions for gadotic acid at a rate below one in 10,000 doses. Still, rare doesn’t mean never.
A bigger worry crops up for people with kidney problems. Gadotic acid gets filtered out of the bloodstream by the kidneys. If kidneys can’t do their job well, gadolinium may hang around longer. Doctors now screen patients carefully. For those with advanced kidney disease, exposure can trigger a condition called nephrogenic systemic fibrosis (NSF). This shows up as thick, hard skin and joint trouble, and at worst, it can affect organs. Thankfully, this has turned up mostly in people with severe kidney failure and nearly vanished since clinics got stricter about patient selection and dosage.
Concerns have grown after research found gadolinium traces in brains and bones, even years after a scan. Nobody has connected these deposits to definite health problems in healthy patients, but major groups like the Radiological Society of North America call for more research and smarter use. Not knowing what this means for people in the long run puts pressure on doctors to balance clarity in imaging with real caution about overuse.
Medical teams now do much more to avoid unnecessary risks. Before any scan, patients fill out health history forms. Clinics track every dose, stick with the lowest effective amount, and keep up with the latest research. For parents or caregivers of children, the principles stay the same — double check the need, keep doses as low as possible, and talk openly about risks versus rewards.
If a patient’s anxious about the test, sharing stories from past patients who did well helps build trust. Healthcare works best when people feel like their questions and discomfort matter, so open lines of communication are part of safer imaging, not just paperwork.
Gadotic acid delivers detailed answers during complicated diagnoses. With each scan, patients and care teams weigh the risks, focus on clear communication, and look to science-backed guidelines before taking the next step. The technology changes, but the need to listen and personalize decisions stays steady.
Gadotic acid plays a big part in magnetic resonance imaging, better known as MRI scans. Many people who need an MRI for clearer pictures of their organs or tissues might hear about this compound, but the way it gets into the body isn’t as widely discussed. Injectable contrast agents like gadotic acid help radiologists spot details that regular scans could miss, giving patients and doctors a better shot at early and accurate diagnoses.
The administration process happens in the controlled setting of a hospital or clinic. A trained technician or nurse uses a sterile needle to inject a measured dose of gadotic acid directly into a patient’s vein. Usually this means a needle slips into the crook of the arm, much like what you’d expect for drawing blood. The medicine enters the bloodstream, reaching the tissues pretty quickly. The timing is set up so the MRI takes place soon after injection, making the most of the agent’s ability to highlight differences in tissues.
Many years in health care show me patients often arrive nervous, unsure what to expect. Gadotic acid goes in smoothly, and most hardly notice a thing beyond a small stick from the needle. The focus stays on patient comfort—experienced staff usually distract with easy conversation while preparing the dose. Sanitation comes first, so all tools and surfaces get a thorough wipe-down, and the drugs come from sealed, regulated vials. The amount depends on the person’s weight; every patient gets an individually calculated dose. Gadotic acid is never a one-size-fits-all solution.
Too little contrast, and the MRI can miss what doctors need to see—tumors, infections, scars on organs. Too much contrast, and a patient might feel sick or face rare but dangerous side effects. Some people have conditions—like weak kidneys—that mean extra caution goes into the decision to give any contrast at all. Hospitals rely on updated protocols and electronic records to track past allergies or reactions, reducing risks related to the injection. This layer of checking protects people and builds trust in the scans’ results.
Questions about side effects are common. From what patients have told me, most experience nothing more than a temporary cool feeling during injection. A few feel slightly nauseous or get a mild headache. Allergic response is rare but taken seriously. Staff keep emergency medications and equipment on hand, just in case. Transparency and calm explanations turn what could be a worrying few minutes into a manageable part of a medical visit.
Reducing unnecessary injections protects both budgets and patient wellbeing. Doctors are shifting toward more evidence-based guidelines, weighing the need for contrast against possible drawbacks. Research into safer alternatives and deeper patient screening moves forward each year, which means the use of gadotic acid only stands to get safer with time. Thoughtful administration keeps patients at the center of the medical process, which should always be the main goal in healthcare.
Gadotic acid crops up every day in radiology departments as a contrast agent for MRI scans. Anyone who’s ever faced an MRI knows there’s already enough to worry about. For kidney patients, one looming question keeps coming up—can their bodies handle this drug safely, or does it invite more trouble?
Doctors order MRI scans for good reasons. Without contrast agents, tumors and other problems often hide away. Gadotic acid makes these problems stand out, but its use can spark concern, especially for people with poor kidney function. Over a decade ago, researchers tied gadolinium-based contrast dyes to a rare but devastating disease called nephrogenic systemic fibrosis (NSF). People with advanced kidney failure, dialysis patients, and those teetering on the edge of renal trouble saw the highest risk of this condition, which leaves skin thick and joints stiff.
Medicine learned the hard way about contrast risks. As a young radiology tech years ago, I watched nervous reactions ripple through our department every time a nephrology consult flagged up. The memory of cases linked to NSF hasn't faded—those scars run deep in hospitals. Reports from the FDA and a raft of journals since 2006 drove new rules. Suddenly, teams started checking kidney bloodwork before every enhanced MRI. If someone’s glomerular filtration rate (GFR) stood below 30, alarms went off. Gadotic acid and its cousins got locked away for most of these patients.
These gadolinium agents don't all act the same way. The chemical shape matters. Gadotic acid belongs in the “macrocyclic” class—a design that holds onto gadolinium more tightly than older “linear” agents. Big studies found macrocyclic agents like gadotic acid rarely deposit gadolinium in body tissues, and almost never trigger NSF in patients with mild to moderate kidney dysfunction. The risks climb in people with severe chronic kidney disease or dialysis, though, so careful screening remains important.
Professional groups like the American College of Radiology outline clear use cases. If a patient has chronic kidney disease stage IV or V, gadotic acid only enters the equation if alternatives don’t exist and diagnostic answers will affect urgent treatment. Most centers use the lowest possible dose, track GFR, and involve nephrology for anyone skating on thin ice. In my own practice, these consults slow things down, but they’re a small price to pay compared to causing lifelong disability.
Better awareness and new protocols cut the risk dramatically in the past decade. Radiologists now reserve gadotic acid for the right moments. For critical cases with tough kidney issues, switching to non-contrast MRI, ultrasound, or even skipping unnecessary scans often keeps people safer. Plain communication with patients helps, too. No one likes surprises, especially about long-term side effects. I’ve seen patients relax when we take that extra time, translating jargon and walking through options.
Future research still needs to lock down the tiny risks and improve alternatives. Until then, nothing replaces careful judgment. Saying “no” to unnecessary contrast is an act of care, not an oversight. As medicine keeps learning, practical safety steps and honest conversations keep kidney patients from facing risks they never signed up for in the first place.
Honesty makes a difference before any scan with contrast agents like Gadotic Acid. People often leave out those small health details because they don’t seem important, but clear communication with your doctor matters. Kidney issues stand out as a key factor. Gadotic Acid, like other gadolinium-based contrast agents, passes through the kidneys. Poor kidney function can lead to a rare but serious condition called nephrogenic systemic fibrosis. Blood tests aren’t fun, but a quick check of kidney function can save a world of trouble later.
Anyone with a history of allergic reactions to contrast agents or similar chemicals should speak up. Stories circulate about someone ending up wheezing, dizzy, and scared in a hospital hallway after contrast administration. Even if you’ve usually tolerated contrast before, sensitivities change. Your doctor should hear about any past hives, difficulty breathing, or unexplained rashes after scans. Bringing up any allergies—shellfish, medications, or food—helps form a clearer picture, since multiple allergies can increase the overall risk.
Pills, supplements, and vitamins go into your body and can interact with medical treatments. Gadotic Acid doesn’t mix with everything. For instance, metformin, a common diabetes drug, has launched confusion and even rare kidney issues during contrast scans. A thorough medication review means fewer surprises. Listing prescriptions, over-the-counter drugs, and herbal supplements on a notecard and bringing it to your appointment lets your care team spot problems early.
Talking about family planning may feel awkward, especially when coming in for an MRI. Pregnant or breastfeeding patients face additional concerns. Current guidelines suggest minimizing Gadotic Acid use during pregnancy unless absolutely necessary. Gadolinium can cross the placental barrier, and its full effects on the fetus remain unknown. For those breastfeeding, pumping and discarding breast milk for a day after the scan reduces infant exposure. Open conversations with your provider allow safer planning.
Personal and family health histories should not get brushed aside during intake. Autoimmune diseases, asthma, or heart problems can each bump up risk during administration of contrast. Sharing previous experiences—dizziness, pain, or itching after medical procedures—helps build a detailed risk profile. Healthcare teams work best when trust runs both ways.
Finishing the scan doesn’t mean precautions end. Some side effects may crop up after leaving the hospital or clinic. Watching out for swelling, hives, trouble urinating, or pain keeps small problems from growing. If symptoms start, calling medical help beats waiting and wondering.
Big hospitals usually offer plenty of information, but smaller clinics sometimes run short on time or resources. Everyone should have access to clear, simple explanations about what Gadotic Acid does and why precautions matter. Patient-friendly pamphlets or videos can answer questions before the big day arrives. Clinics that encourage patients to ask questions create safer outcomes.
The best outcomes happen when patients stay involved. Reading about procedures ahead of time, preparing questions, and being honest about medical history leads to safer choices. Gadotic Acid has a strong record of success, but careful preparation helps protect kidney function, prevent allergic reactions, and avoid medication problems. Staying proactive with healthcare creates better, worry-free results for everyone involved.
| Names | |
| Preferred IUPAC name | 4-[(8,11-dihydroxy-14-oxo-2,5,8,11,14-pentaazatetracyclo[13.2.2.2²,⁵.2⁶,¹⁰]icosa-1(17),2,5,7,9,11,13,15-octaen-16-yl)acetamido]butanoic acid |
| Other names |
Dotarem Gd-DOTA Gadoterate meglumine Gadoteric acid Acide gadotérique |
| Pronunciation | /ɡæˈdɒtɪk ˈæsɪd/ |
| Identifiers | |
| CAS Number | 15522-50-2 |
| Beilstein Reference | 1714856 |
| ChEBI | CHEBI:71743 |
| ChEMBL | CHEMBL1201194 |
| ChemSpider | 144806 |
| DrugBank | DB00738 |
| ECHA InfoCard | InfoCard: 14d6ec36-1212-4707-97a1-06efbc9f0c80 |
| EC Number | 62009-48-5 |
| Gmelin Reference | 101094 |
| KEGG | D01737 |
| MeSH | D019835 |
| PubChem CID | 441379 |
| RTECS number | MC4660400 |
| UNII | 9G2MAD7JBI |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C16H25GdN4O8 |
| Molar mass | 558.6 g/mol |
| Appearance | White to almost white powder. |
| Odor | Odorless |
| Density | 1.2 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | -2.6 |
| Vapor pressure | Negligible |
| Acidity (pKa) | 2.7 |
| Basicity (pKb) | 1.0 |
| Magnetic susceptibility (χ) | +2050.0e-6 cm³/mol |
| Refractive index (nD) | 1.621 |
| Viscosity | 160.6 mPa·s |
| Dipole moment | 5.24 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 340.6 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | V08CA02 |
| Hazards | |
| Main hazards | May cause allergy or asthma symptoms or breathing difficulties if inhaled. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | H319: Causes serious eye irritation. |
| Precautionary statements | P201, P202, P260, P264, P270, P272, P280, P308+P313, P405, P501 |
| NFPA 704 (fire diamond) | 1-0-0 |
| Lethal dose or concentration | LD50 Intravenous - rat - 8.4 g/kg |
| LD50 (median dose) | LD50 (median dose): 15.6 mmol/kg (rat, intravenous) |
| NIOSH | Not established |
| PEL (Permissible) | 0.1 mg/m3 |
| REL (Recommended) | 0.1 mmol/kg |
| IDLH (Immediate danger) | Not listed. |
| Related compounds | |
| Related compounds |
Gadoterate meglumine Gadopentetic acid Gadoteridol Gadobutrol Gadodiamide |
